Join Bullfrog AI’s Exclusive Live Investor Webinar and Q&A Session on April 23

Rhea-AI Summary

Bullfrog AI Holdings (NASDAQ: BFRG) has announced an exclusive live investor webinar and Q&A session scheduled for April 23, 2025, at 4:15 p.m. ET. The event, hosted by RedChip Companies, will feature CEO Vin Singh discussing the company's innovative approach to drug development using AI and machine learning.

The presentation will showcase their proprietary bfLEAP™ platform, developed at Johns Hopkins Applied Physics Lab and a finalist for the R&D 100 Awards. This platform helps biopharma companies analyze high-dimensional, multi-modal data to optimize clinical strategies. The company's growth strategy focuses on two main areas: generating recurring revenue through their Data Networks platform and developing licensed drug assets in partnership with leading research institutions.

Positive

• Proprietary bfLEAP platform recognized as R&D 100 Awards finalist
• Strategic partnership with Johns Hopkins Applied Physics Lab
• Dual revenue model combining recurring platform revenue and drug asset development

Negative

• None.

GAITHERSBURG, Md., April 17, 2025 (GLOBE NEWSWIRE) -- Bullfrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("Bullfrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, is pleased to invite investors to a webinar on April 23, 2025, at 4:15 p.m. ET.

The exclusive event, hosted by RedChip Companies, will feature Vin Singh, CEO of Bullfrog AI.

Attendees will gain insight into Bullfrog AI’s innovative use of artificial intelligence and machine learning to revolutionize drug development. The Company’s proprietary bfLEAP™ platform, developed at Johns Hopkins Applied Physics Lab and a finalist for the R&D 100 Awards, enables biopharma firms to uncover hidden biological insights and optimize clinical strategies using high-dimensional, multi-modal data. The webinar will highlight Bullfrog’s dual growth strategy—driving recurring revenue through its scalable Data Networks platform while advancing a pipeline of licensed drug assets in collaboration with top-tier research institutions.

A live question and answer session will follow the presentation.

To register for the free webinar, please visit: https://redchip.zoom.us/webinar/register/WN_dCeoUqJ-Q_idZrNzdVAeig#/registration

Questions can be pre-submitted to BFRG@redchip.com or online during the live event.

About Bullfrog AI

Bullfrog AI leverages Artificial Intelligence and machine learning to advance drug discovery and development. Through collaborations with leading research institutions, Bullfrog AI uses causal AI in combination with its proprietary bfLEAP™ platform to analyze complex biological data, aiming to streamline therapeutics development and reduce failure rates in clinical trials.

For more information visit Bullfrog AI at: https://bullfrogai.com

Safe Harbor Statement
This press release contains forward-looking statements. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," “could,” “will,” "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.

Contact:
Dave Gentry
RedChip Companies, Inc.
1-407-644-4256
BFRG@redchip.com

FAQ

When is Bullfrog AI (BFRG) hosting its investor webinar and how can investors participate?

Bullfrog AI's investor webinar is scheduled for April 23, 2025, at 4:15 p.m. ET. Investors can register for free through RedChip's Zoom registration link and can submit questions in advance to BFRG@redchip.com or during the live event.

What is Bullfrog AI's (BFRG) bfLEAP platform and where was it developed?

bfLEAP is Bullfrog AI's proprietary platform developed at Johns Hopkins Applied Physics Lab. It's a finalist for the R&D 100 Awards and helps analyze high-dimensional, multi-modal data for optimizing clinical strategies in drug development.

What is Bullfrog AI's (BFRG) current business growth strategy?

Bullfrog AI pursues a dual growth strategy: generating recurring revenue through their Data Networks platform while developing a pipeline of licensed drug assets in collaboration with research institutions.

How does Bullfrog AI (BFRG) use artificial intelligence in drug development?

Bullfrog AI uses artificial intelligence and machine learning to analyze complex biological data, helping biopharma companies uncover hidden insights and optimize their clinical development strategies.